Three of our top 10 stories of April 2021 highlight new data and ideas presented at this year’s Charing Cross (CX) Symposium, Digital Edition (19–22 April, online), covering the potential of Philips’ Fiber Optic RealShape (FORS) technology to reduce radiation exposure, a call on medical agencies to change their paclitaxel recommendations in peripheral arteries, and two-year IN.PACT AV Access results. Last month, the world’s first accreditation programme for interventional oncology also opened for enrolment, and Interventional News readers heard about the latest offerings from Philips Healthcare.
1. IASIOS, the world’s first accreditation programme for interventional oncology, just opened for public enrolment
The International Accreditation System for Interventional Oncology Services (IASIOS) is now open for public enrolment, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has announced. Twelve pioneering hospitals from nine countries participated in the IASIOS pilot phase, and the accrediting system, tested and optimised over the past two years, now stands ready to accept applications from facilities offering interventional oncology (IO) services worldwide, regardless of the institution’s size or location.
Opening the CX 2021 Digital Edition, experts deliberated crucial controversies in the abdominal aortic space. Discussion emphasised the potential of Philips’ Fiber Optic RealShape (FORS) technology to reduce radiation and ease technical success, with moderator Gustavo Oderich (Houston, USA) suggesting that “radiation will be a thing of the past” thanks to this new technology. Other key takeaways were a ringing endorsement that endoanchors have a part to play in the treatment of challenging necks, and consensus among the panel that parallel grafts should be used as little as possible in this hostile anatomy.
3. New figures show the NHS needs thousands more radiologists to keep patients safe, with a post-COVID consultant exodus also looming
More than half (58%) of radiology leaders say they do not have enough diagnostic and interventional radiologists to keep patients safe, new data from National Health Service (NHS) trusts and health boards across the UK show. The data, recently published in a Royal College of Radiologists (RCR) report, also show that, despite many imaging doctors staying in the NHS last year to help the coronavirus effort, the NHS radiologist workforce is now short-staffed by 33% and needs at least another 1,939 consultants to meet safe staffing levels and pre-coronavirus levels of demand for scans.
In a Philips-sponsored video, Constantino Peña (Miami, USA) moderates an Interventional News webinar focusing on how the SmartCT system (Philips) can “transform” interventional radiology (IR) suites and the importance of 3D imaging within this setting. Peña is joined by two early-users of the technology, Marc Sapoval and Hicham Kobeiter, both from Paris, France.
5. CX audience supports call to change agency recommendations regarding paclitaxel use in peripheral interventions
Addressing representatives from the US Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) directly, Thomas Zeller (Bad Krozingen, Germany) argued at the CX Digital Edition 2021 that “it is time to change the agency recommendations regarding paclitaxel use in peripheral interventions”. Moderators Andrew Holden (Auckland, New Zealand) and Gunnar Tepe (Rosenhein, Germany), Podium 1st presenters Gary Ansel (Columbus, USA) and William Gray (Wynnewood, USA), as well as a 71% majority of the CX audience, supported this view.
Soundbite Medical Solutions has announced US Food and Drug Administration (FDA) 510(k) approval for the SoundBite crossing system—Peripheral (SCS-P) with the 0.014” active wire (14P).
Shivank Bhatia and Vedant Acharya highlight the importance of multidisciplinary collaboration between urologists and interventional radiologists when it comes to forming a successful prostate artery embolization (PAE) clinic, citing a decade of experience at the Miami Miller School of Medicine (Miami, USA).
The results of a two-year study support the continued safety and effectiveness of the Zilver Vena Venous Stent (Cook Medical) in treating symptomatic iliofemoral venous outflow obstruction, according to findings presented at the 2021 meeting of the Society of Interventional Radiology (SIR; 20–26 March, online).
Last month, Medtronic announced the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study. The data, which were presented virtually as a Podium 1st at the CX 2021 Digital Edition, demonstrated that the IN.PACT AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.
10. Superficial tunnelling technique not associated with patency or amputation in patients with limb ischaemia
The results of a recent investigation have revealed no association between infrainguinal bypass tunnelling technique and primary outcomes in patients with limb ischaemia. “Compared to subfascial tunnelling,” write Nallely Saldana-Ruiz (University of Southern California, Los Angeles, USA) and colleagues in the Journal of Vascular Surgery (JVS), “the superficial tunnelling technique is not associated with primary patency or major amputation in limb ischaemia patients undergoing infrainguinal bypass with a single-segment great saphenous vein”.